Latest News

Apr 27, 2017

Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP

Safe Starting Dose for First-In-Human Studies Defined, Clinical Development Stage Commences MELBOURNE, AUSTRALIA -- (Marketwired) -- 04/27/17 -- Propanc Biopharma, Inc. (OTCQB: PPCH) (OTCQB:…

View All Press Releases